SHANGHAI and SUZHOU, China , Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma , a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101 , the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology.

"This is a critical milestone for Phrontline as we advance our mission to deliver innovative ADC therapies that can meaningfully impact patients' lives," said Zhaoyuan "Tony" Chen, Chief Executive Officer of Phrontline Biopharma . "The initiation of this study not only represents the progress of our lead candidate, TJ101, but also demonstrates the strength of our platform and the dedication of

See Full Page